The Velogica team has been able to update the automated underwriting engine quickly in response to the COVID-19 pandemic. New testing reached the public rapidly with ExamOne and LabCorp as main recipients, and new LOINCs (Logical Observation Identifiers Names and Codes) were created to match with each unique test kit. Velogica’s integration with ExamOne LabPiQture has allowed us to identify these seamlessly.
If a LOINC code is found in the ExamOne LabPiQture data source matching COVID-19, and results in anything other than a qualitative or quantitative ‘Non-Detected’, we will refer the case for further review.
There has also been much consideration regarding the use of chloroquine and hydroxychloroquine, two medicines currently authorized to treat malaria and certain autoimmune diseases, to treat COVID-19. Although still in clinical trials, Velogica customized the rules so when the prescription database shows a new presence of these medications, it is coded to mirror the carrier’s internal guidelines.
Evidence of COVID-19 either from prescriptions or clinical labs will be easily communicated through the output of the Velogica system so the carrier can proceed accordingly.
We will continue to monitor effective treatment plans and provide associated evaluations as the medical approach to this disease continues to evolve.
